Taro Pharma (TARO) Reports Q4 EPS of $3.42
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Taro Provides Results for December 31, 2016
February 9, 2017 5:05 PM ESTHAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the three and nine months ended December 31, 2016.
Quarter ended December 31, 2016 Highlights - compared to December 31, 2015
Net sales of $220.4 million, decreased $37.9 million, or 14.7%, the result of continuing increased competition and the challenging pricing environment. Overall volumes increased 1%. Gross profit of $167.3 million decreased $46.8 million, and as a percentage of net sales, was 75.9% compared to 82.9%. Research and development expenses remained in line with the comparable quarter at... More